A Phase 3 interventional study of V503 in Cervical Cancers, Vulvar Cancer and Vaginal Cancer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 9 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-03.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms — 6 open to participants now, 8 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Uterine Cervical Neoplasms.
Among the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2009, is one of 9 in phase 3, and was the 1st registered.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →6 of the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Shanghai Bovax Biotechnology Co., Ltd. · Sites in China
Ages 9–45 · Women only · Healthy volunteers
Miriam Elfström · Sites in Sweden
Ages 22–27 · Women only
Institut d'Investigació Biomèdica de Bellvitge · Sites in Sierra Leone
Ages 18–29 · Women only
National Institute of Hygiene and Epidemiology, Vietnam · Sites in Australia, Vietnam
Ages 18–26 · Women only · Healthy volunteers
Rwanda Biomedical Centre
Ages 23–29 · Women only · Healthy volunteers
By country, each count listing its studies:
Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 9 Years to 26 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2009.
This study's enrollment of 3,074 is above the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 1,206 across the 14 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 14 have an industry lead sponsor. The 9 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc: 3 open now, 6 under way, 2 of them phase 3. Of 24 finished, 17 (71%) have results posted.
Among the 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc, this one is the 5th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2009, is one of 16 in phase 3, and was the 12th registered.
Merck & Co., Inc’s Uterine Cervical Neoplasms studies by the year they started, since 2001.
2 of the studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06411938Indiana UniversityA Cervical Cancer Prevention Program in Kenya | 2026-12-31 |
| NCT07303751Institut d'Investigació Biomèdica de BellvitgeStudy Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, from their registry updates:
Among Merck & Co., Inc’s 31 in Uterine Cervical Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the immunogenicity and tolerability of V503 (a multivalent human papillomavirus [HPV] L1 virus-like particle [VLP] vaccine) in preadolescent and adolescent participants between 9 and 15 years old and demonstrate the consistency of the manufactured vaccine through assessment of 3 different final manufacturing process lots of V503.
The primary hypotheses are as follows:
The base study V503-002 was a 12-month study that collected immunogenicity data through Month 7 and safety data through Month 12.
An optional extension study (V503-002 EXT1) collected safety and immunogenicity information through Month 36. Participants enrolled in the 16- to 26-year-old cohort in the base study were not included in EXT1. Per protocol, EXT1 included immunogenicity data from a subset of 9- to 15-year-old females and safety data from all 9- to 15-year-old females regardless of lot administered.
An optional second extension study (V503-002 EXT2) collected long-term safety and immunogenicity information through approximately Month 126. No study vaccine was administered in the extension studies. Participants enrolled in the 16- to 26-year-old cohort in the base study were not included in EXT2. Per protocol, EXT2 included immunogenicity data from a subset of 9- to 15-year-old females and effectiveness and safety data from all 9- to 15-year-old females regardless of lot administered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Boys and Girls Age 9 to 15:
Women Age 16 to 26:
Exclusion Criteria:
Boys and Girls Age 9 to 15:
Women Age 16 to 26:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
Biological: V503
9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 2.
Biological: V503
9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 3.
Biological: V503
9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
Biological: V503
9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
Biological: V503
Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.
Base Study: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])
Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.
Time frame: 4 weeks post-vaccination 3 (Month 7)
Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] and 16- to 26-Year-Old Females [Lot 1])
Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.
Time frame: 4 weeks post-vaccination 3 (Month 7)
Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)
Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. Titers were reported in milli Merck Units/mL.
Time frame: 4 weeks post-vaccination 3 (Month 7)
Base Study: Percentage of Participants With Injection Site Adverse Experiences (AEs)
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.
Time frame: Up to 5 days after any vaccination
Base Study: Percentage of Participants With Systemic AEs
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. Systemic AEs were those not categorized as injection-site AEs.
Time frame: Up to 15 days after any vaccination
Base Study: Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC)
Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded. The percentage of participants who had at least 1 oral body temperature reading that was ≥100.0°F (≥37.8ºC) was summarized.
Time frame: Up to 5 days after any vaccination
Extension Study: GMTs For Each of the HPV Types Contained in the Vaccine
Serum antibody titers (milli Merck Units/mL) measured by cLIA to each of the 9vHPV types were assessed. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.
Time frame: Up to ~Month 126
Extension Study: Percentage of Participants Who Are Seropositive to Each of the HPV Types Contained in the Vaccine
Serum antibody titers for HPV VLPs Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined and reported in milli Merck Units/mL. The percentage of participants seropositive to each HPV type was reported. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.
Time frame: Up to ~Month 126
Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])
Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.
Time frame: 4 weeks post-vaccination 3 (Month 7)
Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] Versus 16- to 26-Year-Old Females [Lot 1])
Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.
Time frame: 4 weeks post-vaccination 3 (Month 7)
Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)
Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post- vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.
Time frame: 4 weeks post-vaccination 3 (Month 7)
Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Females
Persistent infection is when a participant is positive by polymerase chain reaction (PCR) for the same HPV type in cervicovaginal/external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later. Per protocol, the extension study included 9- to 15-year-old females regardless of lot administered.
Time frame: Up to ~Month 126
Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Males
Persistent infection is when a participant is positive by PCR for the same HPV type in external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later.
Time frame: Up to ~Month 126
Extension Study: Combined Incidence of Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Genital Warts, and Cervical/Vulvar/Vaginal Cancers Related to HPV 6/11/16/18/31/33/45/52/58 in Females
The combined incidence of cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, and cervical/vulvar/vaginal cancers, related to HPV 6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.
Time frame: Up to ~Month 126
Extension Study: Combined Incidence of Penile Intraepithelial Neoplasia, Penile/Perineal/Perianal Cancers and Genital Warts Related to HPV 6/11/16/18/31/33/45/52/58 in Males
The combined incidence of penile intraepithelial neoplasia, penile/perineal/perianal cancers, and genital warts related to HPV6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. For each study participant, person-years follow up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later.
Time frame: Up to ~Month 126
Extension Study: Percentage of Participants With Vaccine-Related or Procedure-Related Serious Adverse Events
A serious adverse event (SAE) included a death which resulted in the participant discontinuing the study, a serious adverse experience that was considered by an investigator who was a qualified physician to be possibly, probably, or definitely vaccine related or study procedure related. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.
Time frame: Up to ~Month 126
The base study was a 12-month study that collected immunogenicity data through Month 7 and safety data through Month 12.
| Milestone | Base Study: 9- to 15-Year-Old Females (Lot 1) | Base Study: 9- to 15-Year-Old Females (Lot 2) | Base Study: 9- to 15-Year-Old Females (Lot 3) | Base Study: 9- to 15-Year-Old Males (Lot 1) | Base Study: 16- to 26-Year-Old Females (Lot 1) | Extension Study: 9- to 15-Year-Old Females | Extension Study: 9- to 15-Year-Old Males |
|---|---|---|---|---|---|---|---|
| Started | 648 | 643 | 644 | 669 | 470 | 0 | 0 |
| Vaccination 1 | 646 | 642 | 644 | 666 | 468 | 0 | 0 |
| Vaccination 2 | 637 | 633 | 638 | 658 | 462 | 0 | 0 |
| Vaccination 3 | 635 | 627 | 637 | 653 | 455 | 0 | 0 |
| At least one dose with protocol-specified safety follow-up | 643 | 639 | 641 | 662 | 466 | 0 | 0 |
| Completed | 623 | 621 | 631 | 647 | 444 | 0 | 0 |
| Not completed | 25 | 22 | 13 | 22 | 26 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 12 | 8 | 10 | 8 | 11 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 12 | 13 | 2 | 13 | 8 | 0 | 0 |
| Withdrew: Month 12 visit not completed | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Milestone | Base Study: 9- to 15-Year-Old Females (Lot 1) | Base Study: 9- to 15-Year-Old Females (Lot 2) | Base Study: 9- to 15-Year-Old Females (Lot 3) | Base Study: 9- to 15-Year-Old Males (Lot 1) | Base Study: 16- to 26-Year-Old Females (Lot 1) | Extension Study: 9- to 15-Year-Old Females | Extension Study: 9- to 15-Year-Old Males |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 1604 | 568 |
| Completed | 0 | 0 | 0 | 0 | 0 | 1489 | 527 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 115 | 41 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 38 | 10 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 32 | 10 |
| Withdrew: Disposition unknown | 0 | 0 | 0 | 0 | 0 | 44 | 21 |
| Milestone | Base Study: 9- to 15-Year-Old Females (Lot 1) | Base Study: 9- to 15-Year-Old Females (Lot 2) | Base Study: 9- to 15-Year-Old Females (Lot 3) | Base Study: 9- to 15-Year-Old Males (Lot 1) | Base Study: 16- to 26-Year-Old Females (Lot 1) | Extension Study: 9- to 15-Year-Old Females | Extension Study: 9- to 15-Year-Old Males |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 971 | 301 |
| Completed | 0 | 0 | 0 | 0 | 0 | 720 | 202 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 251 | 99 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 111 | 46 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 137 | 50 |
Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.
| milli Merck Units/mL | Base Study: 9- to 15-Year-Old Females (Lot 1) | Base Study: 9- to 15-Year-Old Males (Lot 1) |
|---|---|---|
| Anti-HPV 6 | 1715.4 (1595.1 to 1844.7) | 900.8 (822.3 to 986.9) |
| Anti-HPV 11 | 1295.1 (1204.1 to 1393.0) | 706.6 (645.2 to 773.8) |
| Anti-HPV 16 | 6979.8 (6508.1 to 7485.8) | 3522.6 (3223.5 to 3849.5) |
| Anti-HPV 18 | 2153.7 (1980.4 to 2342.1) | 882.7 (795.4 to 979.5) |
| Anti-HPV 31 | 1891.6 (1745.7 to 2049.7) | 753.9 (682.5 to 832.7) |
| Anti-HPV 33 | 980.4 (911.7 to 1054.3) | 466.8 (426.9 to 510.3) |
| Anti-HPV 45 | 714.4 (651.9 to 782.8) | 272.2 (243.8 to 303.9) |
| Anti-HPV 52 | 932.9 (864.8 to 1006.4) | 419.6 (381.4 to 461.5) |
| Anti-HPV 58 | 1286.7 (1195.7 to 1384.6) | 590.5 (538.2 to 647.9) |
Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.
| milli Merck Units/mL | Base Study: 9- to 15-Year-Old Males (Lot 1) | Base Study: 16- to 26-Year-Old Females (Lot 1) |
|---|---|---|
| Anti-HPV 6 | 2084.7 (1944.0 to 2235.7) | 900.8 (822.3 to 986.9) |
| Anti-HPV 11 | 1487.1 (1386.5 to 1595.0) | 706.6 (645.2 to 773.8) |
| Anti-HPV 16 | 8628.9 (8065.9 to 9231.3) | 3522.6 (3223.5 to 3849.5) |
| Anti-HPV 18 | 2822.8 (2602.8 to 3061.5) | 882.7 (795.4 to 979.5) |
| Anti-HPV 31 | 2221.2 (2056.1 to 2399.5) | 753.9 (682.5 to 832.7) |
| Anti-HPV 33 | 1198.7 (1117.1 to 1286.2) | 466.8 (426.9 to 510.3) |
| Anti-HPV 45 | 907.0 (830.2 to 991.0) | 272.2 (243.8 to 303.9) |
| Anti-HPV 52 | 1037.8 (964.4 to 1116.9) | 419.6 (381.4 to 461.5) |
| Anti-HPV 58 | 1567.7 (1460.2 to 1683.1) | 590.5 (538.2 to 647.9) |
Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. Titers were reported in milli Merck Units/mL.
| milli Merck Units/mL | Base Study: 9- to 15-Year-Old Females (Lot 1) | Base Study: 9- to 15-Year-Old Females (Lot 2) | Base Study: 9- to 15-Year-Old Females (Lot 3) |
|---|---|---|---|
| Anti-HPV 6 | 1715.4 (1588.7 to 1852.2) | 1763.3 (1635.4 to 1901.3) | 1659.9 (1540.3 to 1788.7) |
| Anti-HPV 11 | 1295.1 (1197.8 to 1400.3) | 1311.7 (1214.9 to 1416.3) | 1232.0 (1141.7 to 1329.5) |
| Anti-HPV 16 | 6979.8 (6476.1 to 7522.8) | 7292.9 (6772.7 to 7853.1) | 6948.2 (6458.7 to 7474.9) |
| Anti-HPV 18 | 2153.7 (1970.9 to 2353.5) | 2134.1 (1955.6 to 2329.0) | 1966.6 (1804.3 to 2143.5) |
| Anti-HPV 31 | 1891.6 (1738.5 to 2058.2) | 1867.8 (1719.3 to 2029.1) | 1879.0 (1731.0 to 2039.6) |
| Anti-HPV 33 | 980.4 (909.2 to 1057.2) | 922.7 (856.2 to 994.4) | 931.1 (865.0 to 1002.3) |
| Anti-HPV 45 | 714.4 (650.1 to 785.0) | 827.7 (754.1 to 908.5) | 678.4 (619.0 to 743.6) |
| Anti-HPV 52 | 932.9 (860.8 to 1011.0) | 1007.9 (931.0 to 1091.2) | 971.2 (898.1 to 1050.3) |
| Anti-HPV 58 | 1286.7 (1190.0 to 1391.3) | 1344.9 (1244.6 to 1453.3) | 1208.1 (1119.6 to 1303.6) |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.
| Percentage of Participants | 9- to 15-Year-Old Females (Lots 1, 2 or 3) | Base Study: 9- to 15-Year-Old Males (Lot 1) | Base Study: 16- to 26-Year-Old Females (Lot 1) |
|---|---|---|---|
| Base Study: Percentage of Participants With Injection Site Adverse Experiences (AEs) | 81.9 | 72.8 | 85.4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. Systemic AEs were those not categorized as injection-site AEs.
| Percentage of Participants | 9- to 15-Year-Old Females (Lots 1, 2 or 3) | Base Study: 9- to 15-Year-Old Males (Lot 1) | Base Study: 16- to 26-Year-Old Females (Lot 1) |
|---|---|---|---|
| Base Study: Percentage of Participants With Systemic AEs | 45.0 | 41.8 | 57.1 |
Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded. The percentage of participants who had at least 1 oral body temperature reading that was ≥100.0°F (≥37.8ºC) was summarized.
| Percentage of Participants | 9- to 15-Year-Old Females (Lots 1, 2, or 3) | Base Study: 9- to 15-Year-Old Males (Lot 1) | Base Study: 16- to 26-Year-Old Females (Lot 1) |
|---|---|---|---|
| Base Study: Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC) | 8.4 | 10.0 | 8.4 |
Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.
| Percentage of Participants | Base Study: 9- to 15-Year-Old Females (Lot 1) | Base Study: 9- to 15-Year-Old Males (Lot 1) |
|---|---|---|
| Anti-HPV 6 cLIA ≥30 mMU/mL | 99.8 (98.9 to 100) | 99.7 (98.3 to 100) |
| Anti-HPV 11 cLIA ≥16 mMU/mL | 100 (99.3 to 100.0) | 100 (98.9 to 100.0) |
| Anti-HPV 16 cLIA ≥20 mMU/mL | 100 (99.3 to 100.0) | 100 (98.9 to 100.0) |
| Anti-HPV 18 cLIA ≥24 mMU/mL | 99.8 (99.0 to 100.0) | 99.7 (98.4 to 100.0) |
| Anti-HPV 31 cLIA ≥10 mMU/mL | 100.0 (99.3 to 100.0) | 99.7 (98.4 to 100.0) |
| Anti-HPV 33 cLIA ≥8 mMU/mL | 100.0 (99.3 to 100.0) | 99.7 (98.4 to 100.0) |
| Anti-HPV 45 cLIA ≥8 mMU/mL | 99.8 (99.0 to 100.0) | 99.5 (98.1 to 99.9) |
| Anti-HPV 52 cLIA ≥8 mMU/mL | 100.0 (99.3 to 100.0) | 99.7 (98.4 to 100.0) |
| Anti-HPV 58 cLIA ≥8 mMU/mL | 100.0 (99.3 to 100.0) | 100.0 (98.9 to 100.0) |
Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.
| Percentage of Participants | Base Study: 9- to 15-Year-Old Males (Lot 1) | Base Study: 16- to 26-Year-Old Females (Lot 1) |
|---|---|---|
| Anti-HPV 6 cLIA ≥30 mMU/mL | 99.8 (99.0 to 100.0) | 99.7 (98.3 to 100.0) |
| Anti-HPV 11 cLIA ≥16 mMU/mL | 100.0 (99.3 to 100.0) | 100.0 (98.9 to 100.0) |
| Anti-HPV 16 cLIA ≥20 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (98.9 to 100.0) |
| Anti-HPV 18 cLIA ≥24 mMU/mL | 100.0 (99.4 to 100.0) | 99.7 (98.4 to 100.0) |
| Anti-HPV 31 cLIA ≥10 mMU/mL | 100.0 (99.3 to 100.0) | 99.7 (98.4 to 100.0) |
| Anti-HPV 33 cLIA ≥8 mMU/mL | 100.0 (99.4 to 100.0) | 99.7 (98.4 to 100.0) |
| Anti-HPV 45 cLIA ≥8 mMU/mL | 100.0 (99.4 to 100.0) | 99.5 (98.1 to 99.9) |
| Anti-HPV 52 cLIA ≥8 mMU/mL | 100.0 (99.4 to 100.0) | 99.7 (98.4 to 100.0) |
| Anti-HPV 58 cLIA ≥8 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (98.9 to 100.0) |
Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post- vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.
| Percentage of Participants | Base Study: 9- to 15-Year-Old Females (Lot 1) | Base Study: 9- to 15-Year-Old Females (Lot 2) | Base Study: 9- to 15-Year-Old Females (Lot 3) |
|---|---|---|---|
| HPV 6 cLIA ≥30 mMU/mL | 99.8 (98.9 to 100.0) | 99.8 (99.0 to 100.0) | 99.3 (98.1 to 99.8) |
| HPV 11 cLIA ≥16 mMU/mL | 100.0 (99.3 to 100.0) | 100.0 (99.3 to 100.0) | 99.6 (98.7 to 100.0) |
| HPV 16 cLIA ≥20 mMU/mL | 100.0 (99.3 to 100.0) | 100.0 (99.3 to 100.0) | 99.6 (98.7 to 100.0) |
| HPV 18 cLIA ≥24 mMU/mL | 99.8 (99.0 to 100.0) | 100.0 (99.3 to 100.0) | 99.6 (98.7 to 100.0) |
| HPV 31 cLIA ≥10 mMU/mL | 100.0 (99.3 to 100.0) | 100.0 (99.3 to 100.0) | 99.8 (99.0 to 100.0) |
| HPV 33 cLIA ≥8 mMU/mL | 100.0 (99.3 to 100.0) | 100.0 (99.3 to 100.0) | 99.6 (98.7 to 100.0) |
| HPV 45 cLIA ≥8 mMU/mL | 99.8 (99.0 to 100.0) | 100.0 (99.3 to 100.0) | 99.6 (98.7 to 100.0) |
| HPV 52 cLIA ≥8 mMU/mL | 100.0 (99.3 to 100.0) | 100.0 (99.3 to 100.0) | 99.6 (98.7 to 100.0) |
| HPV 58 cLIA ≥8 mMU/mL | 100.0 (99.3 to 100.0) | 100.0 (99.3 to 100.0) | 99.6 (98.7 to 100.0) |
Serum antibody titers (milli Merck Units/mL) measured by cLIA to each of the 9vHPV types were assessed. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.
| milli Merck Units/mL | Extension Study: 9- to 15-Year-Old Females | Extension Study: 9- to 15-Year-Old Males |
|---|---|---|
| Anti-HPV 6 | 122.3 (111.1 to 134.7) | 129.5 (112.5 to 149.1) |
| Anti-HPV 11 | 80.2 (72.5 to 88.8) | 91.0 (78.4 to 105.6) |
| Anti-HPV 16 | 403.0 (357.3 to 454.5) | 414.3 (353.8 to 485.3) |
| Anti-HPV 18 | 128.1 (116.7 to 140.7) | 148.4 (130.2 to 169.2) |
| Anti-HPV 31 | 108.9 (97.6 to 121.6) | 128.6 (111.2 to 148.8) |
| Anti-HPV 33 | 59.2 (53.7 to 65.2) | 69.6 (60.7 to 79.7) |
| Anti-HPV 45 | 42.1 (37.7 to 47.1) | 49.8 (43.0 to 57.8) |
| Anti-HPV 52 | 55.3 (50.5 to 60.6) | 59.6 (52.0 to 68.4) |
| Anti-HPV 58 | 76.5 (69.2 to 84.6) | 90.5 (78.4 to 104.6) |
Serum antibody titers for HPV VLPs Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined and reported in milli Merck Units/mL. The percentage of participants seropositive to each HPV type was reported. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.
| Percentage of Participants | Extension Study: 9- to 15-Year-Old Females | Extension Study: 9- to 15-Year-Old Males |
|---|---|---|
| Anti-HPV 6 | 82.7 (78.3 to 86.6) | 84.1 (77.8 to 89.2) |
| Anti-HPV 11 | 85.2 (81.0 to 88.9) | 87.0 (81.0 to 91.7) |
| Anti-HPV 16 | 97.3 (95.0 to 98.8) | 98.3 (95.0 to 99.6) |
| Anti-HPV 18 | 80.1 (75.5 to 84.2) | 83.7 (77.4 to 88.8) |
| Anti-HPV 31 | 90.1 (86.4 to 93.0) | 92.7 (87.8 to 96.0) |
| Anti-HPV 33 | 85.2 (81.0 to 88.8) | 89.3 (83.8 to 93.4) |
| Anti-HPV 45 | 81.8 (77.2 to 85.9) | 92.3 (87.2 to 95.8) |
| Anti-HPV 52 | 88.2 (84.4 to 91.4) | 89.2 (83.7 to 93.4) |
| Anti-HPV 58 | 96.5 (94.0 to 98.2) | 97.1 (93.5 to 99.1) |
Persistent infection is when a participant is positive by polymerase chain reaction (PCR) for the same HPV type in cervicovaginal/external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later. Per protocol, the extension study included 9- to 15-year-old females regardless of lot administered.
| Cases per 10,000 person-years | Extension Study: 9- to 15-Year-Old Females |
|---|---|
| Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Females | 52.4 ± 33.6 |
Persistent infection is when a participant is positive by PCR for the same HPV type in external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later.
| Cases per 10,000 person-years | Extension Study: 9- to 15-Year-Old Males |
|---|---|
| Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Males | 54.6 ± 21.9 |
The combined incidence of cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, and cervical/vulvar/vaginal cancers, related to HPV 6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.
| Cases per 10,000 person-years | Extension Study: 9- to 15-Year-Old Females |
|---|---|
| Extension Study: Combined Incidence of Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Genital Warts, and Cervical/Vulvar/Vaginal Cancers Related to HPV 6/11/16/18/31/33/45/52/58 in Females | 2.2 ± 0.1 |
The combined incidence of penile intraepithelial neoplasia, penile/perineal/perianal cancers, and genital warts related to HPV6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. For each study participant, person-years follow up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later.
| Cases per 10,000 person-years | Extension Study: 9- to 15-Year-Old Males |
|---|---|
| Extension Study: Combined Incidence of Penile Intraepithelial Neoplasia, Penile/Perineal/Perianal Cancers and Genital Warts Related to HPV 6/11/16/18/31/33/45/52/58 in Males | 0.0 ± 0.0 |
A serious adverse event (SAE) included a death which resulted in the participant discontinuing the study, a serious adverse experience that was considered by an investigator who was a qualified physician to be possibly, probably, or definitely vaccine related or study procedure related. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.
| Percentage of Participants | Extension Study: 9- to 15-Year-Old Females | Extension Study: 9- to 15-Year-Old Males |
|---|---|---|
| Extension Study: Percentage of Participants With Vaccine-Related or Procedure-Related Serious Adverse Events | 0.0 | 0.0 |
Collected over Base Study: Up to ~12 months; Extension Study: Up to ~126 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Base Study: 9- to 15-Year-Old Females (Lot 1) | 0/648 (0%) | 6/643 (0.9%) | 538/643 (83.7%) |
| Base Study: 9- to 15-Year-Old Females (Lot 2) | 0/643 (0%) | 2/639 (0.3%) | 537/639 (84%) |
| Base Study: 9- to 15-Year-Old Females (Lot 3) | 0/644 (0%) | 8/641 (1.2%) | 554/641 (86.4%) |
| Base Study: 9- to 15-Year-Old Males (Lot 1) | 0/669 (0%) | 11/662 (1.7%) | 505/662 (76.3%) |
| Base Study: 16- to 26-Year-Old Females (Lot 1) | 0/470 (0%) | 15/466 (3.2%) | 404/466 (86.7%) |
| EXT1: 9- to 15-Year-Old Females | 1/1,604 (0.1%) | 2/1,604 (0.1%) | 0/1,604 (0%) |
| EXT1: 9- to 15-Year-Old Males | 0/568 (0%) | 0/568 (0%) | 0/568 (0%) |
| EXT2: 9- to 15-Year-Old Females | 1/971 (0.1%) | 3/971 (0.3%) | 0/971 (0%) |
| EXT2: 9- to 15-Year-Old Males | 0/301 (0%) | 0/301 (0%) | 0/301 (0%) |
| Event | Base Study: 9- to 15-Year-Old Females (Lot 1) | Base Study: 9- to 15-Year-Old Females (Lot 2) | Base Study: 9- to 15-Year-Old Females (Lot 3) | Base Study: 9- to 15-Year-Old Males (Lot 1) | Base Study: 16- to 26-Year-Old Females (Lot 1) | EXT1: 9- to 15-Year-Old Females | EXT1: 9- to 15-Year-Old Males | EXT2: 9- to 15-Year-Old Females | EXT2: 9- to 15-Year-Old Males |
|---|---|---|---|---|---|---|---|---|---|
| Abortion inducedSurgical and medical procedures | 0/643 | 1/639 | 0/641 | 0/662 | 5/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| AppendicitisInfections and infestations | 1/643 | 1/639 | 0/641 | 3/662 | 0/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| Abdominal painGastrointestinal disorders | 0/643 | 0/639 | 0/641 | 0/662 | 1/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| Biliary colicHepatobiliary disorders | 0/643 | 0/639 | 0/641 | 0/662 | 1/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| Urinary tract infectionInfections and infestations | 0/643 | 0/639 | 0/641 | 0/662 | 1/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| ConcussionInjury, poisoning and procedural complications | 0/643 | 0/639 | 1/641 | 0/662 | 1/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| Foot fractureInjury, poisoning and procedural complications | 0/643 | 0/639 | 0/641 | 0/662 | 1/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| Gun shot woundInjury, poisoning and procedural complications | 0/643 | 0/639 | 0/641 | 0/662 | 1/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| HeadacheNervous system disorders | 0/643 | 0/639 | 0/641 | 0/662 | 1/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/643 | 0/639 | 0/641 | 0/662 | 1/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| Event | Base Study: 9- to 15-Year-Old Females (Lot 1) | Base Study: 9- to 15-Year-Old Females (Lot 2) | Base Study: 9- to 15-Year-Old Females (Lot 3) | Base Study: 9- to 15-Year-Old Males (Lot 1) | Base Study: 16- to 26-Year-Old Females (Lot 1) | EXT1: 9- to 15-Year-Old Females | EXT1: 9- to 15-Year-Old Males | EXT2: 9- to 15-Year-Old Females | EXT2: 9- to 15-Year-Old Males |
|---|---|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 506/643 | 513/639 | 529/641 | 465/662 | 393/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| Injection site swellingGeneral disorders | 207/643 | 237/639 | 226/641 | 173/662 | 150/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| Injection site erythemaGeneral disorders | 184/643 | 192/639 | 195/641 | 159/662 | 132/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| HeadacheNervous system disorders | 120/643 | 122/639 | 113/641 | 98/662 | 106/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
| PyrexiaGeneral disorders | 76/643 | 57/639 | 64/641 | 84/662 | 43/466 | 0/1604 | 0/568 | 0/971 | 0/301 |
Per protocol, baseline characteristics were analyzed in all participants randomized in the base study.
| Age, Customized(Participants) | Base Study: 9- to 15-Year-Old Females (Lot 1) | Base Study: 9- to 15-Year-Old Females (Lot 2) | Base Study: 9- to 15-Year-Old Females (Lot 3) | Base Study: 9- to 15-Year-Old Males (Lot 1) | Base Study: 16- to 26-Year-Old Females (Lot 1) | Total |
|---|---|---|---|---|---|---|
| 9 to 12 years | 440 | 432 | 432 | 450 | 0 | 1754 |
| 13 to 15 years | 208 | 211 | 212 | 219 | 0 | 850 |
| 16 to 26 years | 0 | 0 | 0 | 0 | 470 | 470 |
| Sex: Female, Male(Participants) | Base Study: 9- to 15-Year-Old Females (Lot 1) | Base Study: 9- to 15-Year-Old Females (Lot 2) | Base Study: 9- to 15-Year-Old Females (Lot 3) | Base Study: 9- to 15-Year-Old Males (Lot 1) | Base Study: 16- to 26-Year-Old Females (Lot 1) | Total |
|---|---|---|---|---|---|---|
| Female | 648 | 643 | 644 | 0 | 470 | 2405 |
| Male | 0 | 0 | 0 | 669 | 0 | 669 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Aug 2009 to primary completion in Apr 2011, 20 months.
Results were first posted in Jan 2015, 3 years 8 months after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 20 months is below that.
Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent